期刊文献+

联苯双酯治疗抗痨药物性肝损害的疗效研究 被引量:3

The curative effect study of Bifendate used for anti-tuberculosis drug-induced liver injury
原文传递
导出
摘要 目的探讨联苯双酯在抗痨药物性肝损害治疗中的疗效和应用价值。方法选用济宁市结核病防治所2011年1月至2014年12月门诊治疗的169例初治结核病患者,按单用联苯双酯、单用甘草酸二胺及联苯双酯、甘草酸二胺两药合用(简称"甘联合用")分为三组。所有患者均采用标准化疗方案治疗,并进行统计学分析。结果肝功能异常治疗7d及14d,单用联苯双酯组有效率分别为59.38%、68.75%,单用甘草酸二胺组有效率分别为53.33%、63.33%,甘联合用组有效率分别为93.33%、96.67%;肝功能轻度损害治疗7d及14d,单用联苯双酯组有效率分别为24.00%、60.00%,单用甘草酸二胺组有效率分别为22.73%、54.55%,甘联合用组有效率分别为60.00%、90.00%。单用联苯双酯组与单用甘草酸二胺组治疗肝功能异常和肝功能轻度损害7d及14d治疗有效率差异无统计学意义(P>0.05)。单用联苯双酯组和单用甘草酸二胺组与甘联合用组治疗肝功能异常和肝功能轻度损害7d及14d治疗有效率比效,差异均有统计学意义(P<0.01)。结论治疗肝功能异常及肝功能轻度损害单用联苯双酯与甘草酸二胺疗效相当,甘联合用时效果更好。 Objective To investigate the curative effect and application value of Bifendate which is used for anti-tuberculosis drug- induced liver injury. Methods Totally 169 initial treated tuberculous patients were assembled intuberculosis prevention and treatment institute of Jining from Jan 2011 to Dec 2014. They were divided randomly to 3 groupswith the usage of Bifendate only,Diammonium Glycyrrhizinate only and both. All the patients were given standardchemotherapy,and the results were statistically analyzed. Results Treating abnormal liver function for 7 days and 14 days,the efficiency of group Bifendate were 59.38%,68.75%,group Diammonium Glycyrrhizinate were 53.33%,63.33%,and groupcombination with two medicines were 93.33%,96.67%. Treating mild liver function injury for 7 days and 14 days,theefficiency of group Bifendate were 24.00%,60.00%,group Diammonium Glycyrrhizinate were 22.73%,54.55%,and groupcombination were 60.00%,90.00%. There were no statistically differences in the efficiency of group Bifendate and groupDiammonium Glycyrrhizinate,with treating abnormal liver function and mild liver function injury for 7 days and 14 days(P〈0.01). Treating mild liver function injury for 7 days and 14 days,the efficiency of group Bifendate were 24.00%,60.00%,groupDiammonium Glycyrrhizinate were 22.73%,54.55%,and group combination were 60.00%,90.00%. There were statisticallydifferences in the efficiency of group combination,compare with group Bifendate and group Diammonium Glycyrrhizinate,withtreating abnormal liver function and mild liver function injury for 7 days and 14 days(P〈0.01). Conclusion Treatingabnormal liver function and mild liver function injury,the curative effect of Bifendate only or Diammonium Glycyrrhizinate onlyis nearly the same,it becomes better when both the medicines are used.
出处 《中国热带医学》 CAS 2015年第7期869-871,共3页 China Tropical Medicine
关键词 结核病 抗痨药物 肝损伤 保肝药 Tuberculosis Anti-tuberculosis drugs Liver injury Hepatoprotectants
  • 相关文献

参考文献9

  • 1贾凡佰,禇华鲁.210例耐多药肺结核患者治疗情况分析[J].中国病原生物学杂志,2013,8(8):721-723. 被引量:6
  • 2梁雁,刘晓,张海燕,崔一民.325例药物性肝损伤分析[J].中国现代应用药学,2010,27(12):1144-1148. 被引量:28
  • 3中华人民共和国卫生部疾病预防控制局,中华人民共和国卫生部医政司,中国疾病预防控制中心.中国结核病防治规划实施工作指南[M]. 2008年版.北京:中国协和医院大学出版社,2009.
  • 4WHO.耐药结核病规划管理指南[M]. 2008年紧急修订版.李亮,徐彩红,游水红,等译.北京:英国国际发展署和美国国际开发署投资出版,2008.
  • 5中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年)[M].北京:人民卫生出版社,2010.25-52.
  • 6Awodele 0,Akintonwa A, Osunkalu VO. Modulatory activity of antioxi-dants against the toxicity of rifampicin in vivo[J]. Rev Inst Med TropSao Paulo, 2010,52(1): 43-46.
  • 7Agal S, Baijal R, Pramanik S, et al. Monitoring and management of anti-tuberculosis drug induced hepatotoxicityfj]. J Gastroenterol Hepatol,2005,20(11): 1745-1752.
  • 8Femandez-Villar A, sopena B,Fernandez-Villar J, et al. The influenceof risk factors on the severity of anti- tuberculosis drug-induced hepa-totoxicity[J]. Int J Tuberc Lung Dis, 2004, 8(12): 1499-1505.
  • 9Huang YS,Chem HD, Su WJ, et al polymorphism of the N- acetyl-transferase 2 gene as a susceptibility risk factor for anti tuberculosisdug-induced hepatitis[J]. Hepatology, 2002, 35(4): 883-889.

二级参考文献32

  • 1谭守勇,陈洪光,关玉华,陈志成.营养辅助治疗复治菌阳肺结核[J].临床肺科杂志,2005,10(2):147-150. 被引量:24
  • 2LAW M, RUDNICKA A R. Statin safety: a systematic review [J]. Am J Cardiol, 2006, 97(S10): 52-60.
  • 3FANJG,CAIXB.Cognition of hepatic safety in using-vastatin agents .中华心血管病杂志,2007,.
  • 4FAN J G, JIA J D. Advances in Fatty Liver Disease Treatment(脂肪性肝病诊疗进展 ) [M]. Beijing: Chinese Medical Multimedia Press, 2006:21-22.
  • 5ZHOUSM,JIAJ.Analysis of696cases on drug-induced hepatic injury .药品评价,2007,.
  • 6LiverDoctorEditorialDepartment.The mortality of drug induced liver disease ranked at the fifth in the world .肝博士,2006,.
  • 7ANDRADE R J, LUCENA M I. Drug-induced hepatotoxicity [J]. N Engl J Med, 2003, 349(20): 1974-1976.
  • 8LIL,WANGJY.Advances in the pathogenesis of drug-induced hepatic injury .复旦学报:医学版,2007,.
  • 9SIERRA F, TORRES D. A concise and structured review of drug-induced toxic hepatic disease [J]. Ann Hepatol, 2004, 3(1):18-25.
  • 10LINJY,DINGRG.Antibacterial drugs and drug-induced hepatic injury .国外医学:药学分册,2006,.

共引文献98

同被引文献36

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部